Sep 12, 2022 / 04:30PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst
Thanks, everyone, for joining us. My name is Tejas Savant, and I'm the Life Science Tools and Diagnostics Analyst at Morgan Stanley. On the stage with me are Chad Robins and Tycho Peterson, CEO and CFO of Adaptive. It's a pleasure to have you guys here.
Questions and Answers:
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity AnalystMaybe, Chad, just to kick things off, big news this morning with the OrbiMed deal. Do you want to just spend a few minutes walking us through how the deal came about? What are the terms? And how do you see it sort of on a go-forward basis, transforming the opportunity for Adaptive?
Chad M. Robins - Adaptive Biotechnologies Corporation - Co-Founder, CEO & Chairman
Yes, sure. But first, Tejas, thanks for having us here. I really appreciate the opportunity -- we're really excited about the OrbiMed deal. And we've been talking about for the last couple of months that we were pursuing a non